What is the official website of NovogeneAIT Genomics ?

The official website of NovogeneAIT Genomics is https://www.novogene.com/amea-en/.

What is NovogeneAIT Genomics's cybersecurity risk score?

NovogeneAIT Genomics has an AI-generated cybersecurity risk score of 750 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has NovogeneAIT Genomics experienced?

According to Rankiteo, NovogeneAIT Genomics currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has NovogeneAIT Genomics been affected by any supply chain cyber incidents ?

According to Rankiteo, NovogeneAIT Genomics has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does NovogeneAIT Genomics have SOC 2 Type 1 certification ?

According to Rankiteo, NovogeneAIT Genomics is not certified under SOC 2 Type 1.

Does NovogeneAIT Genomics have SOC 2 Type 2 certification ?

According to Rankiteo, NovogeneAIT Genomics does not hold a SOC 2 Type 2 certification.

Does NovogeneAIT Genomics comply with GDPR ?

According to Rankiteo, NovogeneAIT Genomics is not listed as GDPR compliant.

Does NovogeneAIT Genomics have PCI DSS certification ?

According to Rankiteo, NovogeneAIT Genomics does not currently maintain PCI DSS compliance.

Does NovogeneAIT Genomics comply with HIPAA ?

According to Rankiteo, NovogeneAIT Genomics is not compliant with HIPAA regulations.

Does NovogeneAIT Genomics have ISO 27001 certification ?

According to Rankiteo,NovogeneAIT Genomics is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does NovogeneAIT Genomics operate in ?

NovogeneAIT Genomics operates primarily in the Biotechnology Research industry.

How many employees does NovogeneAIT Genomics have ?

NovogeneAIT Genomics employs approximately 61 people worldwide.

Does NovogeneAIT Genomics own any subsidiaries ?

NovogeneAIT Genomics presently has no subsidiaries across any sectors.

How many LinkedIn followers does NovogeneAIT Genomics have ?

NovogeneAIT Genomics's official LinkedIn profile has approximately 7,043 followers.

Does NovogeneAIT Genomics have a Crunchbase profile ?

No, NovogeneAIT Genomics does not have a profile on Crunchbase.

Does NovogeneAIT Genomics have a LinkedIn profile ?

Yes, NovogeneAIT Genomics maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novogeneait.

How many cybersecurity incidents has NovogeneAIT Genomics experienced ?

As of September 9, 2026, Rankiteo reports that NovogeneAIT Genomics has not experienced any cybersecurity incidents.

How many peer or competitor companies does NovogeneAIT Genomics have ?

NovogeneAIT Genomics has an estimated 4,758 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

NovogeneAIT Genomics

Boost Score +25 with badge (5 left)

750

/1000

Fair

775

/1000

Fair

NovogeneAIT Genomics Vendor Cyber Rating & Cyber Score

novogene.com

Add Your Compliance Badge

NovogeneAIT Genomics, headquartered in Singapore, is a premier provider of multi-omics services and solutions. Established in 2016 through a strategic joint venture between Novogene and AITbiotech, we have grown to be one of the largest NGS service providers in Southeast Asia. Our unwavering commitment to delivering high-quality, efficient, and cost-effective omics solutions has propelled us to the forefront of genomic research. NovogeneAIT Genomics offers an extensive range of multi-omics services, including genomics, transcriptomics, single-cell/spatial transcriptomics, metagenomics, and proteomics. Operating from our cutting-edge sequencing center in Singapore, we are dedicated to advancing scientific research by providing superior

NovogeneAIT Genomics

NovogeneAIT Genomics CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

NovogeneAIT Genomics Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for NovogeneAIT Genomics

Incidents vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for NovogeneAIT Genomics in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for NovogeneAIT Genomics in 2026.

Incident Types NovogeneAIT Genomics vs Biotechnology Research Industry Avg (This Year)

No incidents recorded for NovogeneAIT Genomics in 2026.

Incident History - NovogeneAIT Genomics (X = Date, Y = Severity)

Loading…

SUBSIDIARY

NovogeneAIT Genomics Subsidiaries

Parent Company

NovogeneAIT Genomics

Biotechnology Research

Website: https://www.novogene.com/amea-en/

Company Size: 61

No subsidiary data available for this company.

Loading…

NovogeneAIT Genomics Similar Companies

Genentech

gene.com

About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.

Agilent Technologies

cb agilent.com

Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.

Eurofins

cb eurofins.com

Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.

Fortrea

fortrea.com

Fortrea (Nasdaq: FTRE) is a leading global clinical research organization (CRO) dedicated to providing innovative clinical development solutions to the life sciences industry. With over 30 years of clinical research experience, Fortrea has evolved from Covance and Labcorp into a pureplay CRO built for biotech, biopharma, medical device and diagnostic innovators. Fortrea collaborates with both emerging and established companies to deliver agile, fit-for-purpose full service (FSO), functional service (FSP) and hybrid solutions. Fortrea provides comprehensive Phase I-IV clinical trial management, clinical pharmacology, and consulting services, backed by deep experience in more than 20 therapeutic areas. Operating in approximately 100 countries, our diverse and talented team brings scientific rigor, operational excellence, and a strong investigator site network to every trial. By combining the best of our legacy experience with forward-thinking innovation, Fortrea brings predictability to clinical trial execution and helps transform aspirations into outcomes. Together, exceptional is possible. Learn more at Fortrea.com

The National Institutes of Health

cb nih.gov

NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement

Thermo Fisher Scientific

thermofisher.com

About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

CSL

cb csl.com

CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra

ICON plc

iconplc.com

Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.

Charles River Laboratories

criver.com

At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL

Loading…

NEWS

NovogeneAIT Genomics CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-86564

SUMMARY

A flaw was found in DPDK lib/vhost. Missing length validation before reading command_data in the virtio-net control-queue handler can cause an out-of-bounds read and a host process crash.

Published

Date2026-09-08

Updated

Date2026-09-08

RISK INFORMATION (Score: 3.3)

cvss3

Base Score: 3.3

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

1.8

REFERENCES

CVE-2026-55250

SUMMARY

Maravel, a PHP framework oriented towards dependency injection, prior to version 10.74.0 has a high-severity Token Replay Vulnerability arising from a structural lifecycle mismatch between stateless token validation engines and high-performance relational caching layers. Any application with low cache memory that causes premature eviction to free up memory and applications running macropay-solutions/maravel-framework that utilize tymon/jwt-auth for API token authentication and blacklist management or any other package that does the same may be affected. This architectural risk might also impact native Laravel applications utilizing cache tags under specific volatile or eviction-capped environments. tymon/jwt-auth automatically probes for cache tag support. If found, it forcefully wraps 14-day token blacklist entries (jti) inside a relational tymon.jwt tag. In environments where the O(1) Atomic Lazy Eviction model is active — either natively inside Maravel-Framework v20.x or manually backported into v10.x via the explicit DI container singletons provided in PR #104 (App\Cache\TaggedCache and App\Cache\TagSet) — a strict global tracking ceiling (Container::TAGGED_CACHE_TTL_CAP_SECONDS) of 7,200 seconds (2 hours) is enforced to secure the system against memory index bloat. This ceiling forcefully truncates the 14-day blacklist lifespan down to a maximum of 2 hours, after which individual tracking keys naturally expire and disappear from the active cache window. Furthermore, because the optimized engine implements a generational version matrix to achieve O(1) flush speeds, any programmatic or manual invocation of a tag flush or reset (e.g., Cache::tags([...])->flush()) instantly bumps the internal atomic master version pointer. This shifts the computed cryptographic composite hash (sha1($this->tags->getNamespace())) for all overlapping components, rendering the entire existing index immediately unreachable. Consequently, through either natural 2-hour expiration or an intervening tag flush execution (like the cache naturally cleaning old values to free up memory), the invalidation state records are entirely wiped out. Because the tokens' physical cryptographic signatures remain structurally valid for up to 14 days, stolen, hijacked, or legitimately logged-out tokens are instantly and silently resurrected across the entire API gateway, leaving the application critically vulnerable to widespread Token Replay Attacks. Because this issue is caused by an upstream architectural assumption within the tymon/jwt-auth package rather than a core defect inside the framework, there is no direct framework version upgrade that can safely bypass this lifecycle collision without breaking business cache recycling bounds. Maravel version 10.74.0 introduced a way to backport the new fixed tagged cache from 20.x into 10.x by resolving TagSet and TaggedCache from DI, which is how this latent architectural lifecycle vulnerability was discovered. Users must apply the decoupled configuration workaround outlined below. As a workaround, make sure that cache memory size does not generate early natural evictions from cache to free up space, deleting blacklisted jwt ids before they expire. Applications must decouple flat authentication vectors from the relational tagging subsystem. This forces token identifiers to write directly to the primary cache keyspace as flat, un-tagged key-value pairs where they securely retain their unclipped 14-day lifecycle.

Published

Date2026-09-08

Updated

Date2026-09-08

RISK INFORMATION (Score: )

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-53639

SUMMARY

Sylius is an Open Source eCommerce Framework on Symfony. Starting in version 2.0.0 and prior to version 2.0.18, 2.1.15, and 2.2.6, the `GET /api/v2/shop/payment-requests/{hash}` and `PUT /api/v2/shop/payment-requests/{hash}` endpoints look up the payment request solely by the hash from the URL. No ownership check is performed against the authenticated customer or the underlying order. An attacker who obtains a payment request hash can read the payment request and, through the `payment` IRI in the response, recover the underlying order's `tokenValue` (which itself grants access to the full order, items, addresses, customer email, totals); and/or update the payment request payload (e.g. `target_path`, `after_path`). These fields are used by the front-end controller to redirect the user after the payment, so an attacker can flip them to an attacker-controlled URL and intercept the buyer. The hash is a UUID, so it has to be obtained out-of-band (logs, shared links, referrer headers, a co-located client), but once it is known no other credential is required, neither authentication nor knowledge of the order token. The creation endpoint `POST /api/v2/shop/orders/{tokenValue}/payment-requests` shares the same flaw: it resolves the target order solely from the `tokenValue` in the URL without verifying that the caller owns the order. The issue is fixed in versions 2.0.18, 2.1.15, and 2.2.6. As a workaround, add a query extension that filters the `GET` operation; decorate the `PUT` state provider, guard the `POST` creation endpoint with a command-bus middleware, and wire the services.

Published

Date2026-09-08

Updated

Date2026-09-08

RISK INFORMATION (Score: )

cvss4

Base Score: 6.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:L/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://github.com/Sylius/Sylius/security/advisories/GHSA-mr9r-h354-966r

CVE-2026-53638

SUMMARY

Sylius is an Open Source eCommerce Framework on Symfony. Starting in version 2.0.0 and prior to version 2.0.18, 2.1.15, and 2.2.6, an authorization bypass vulnerability exists in the shop account API. The `PATCH /api/v2/shop/account/orders/{tokenValue}/payments/{paymentId}` endpoint, used by an authenticated shop customer to change the payment method of an order that has been placed but not yet paid (state `STATE_NEW`), does not validate that the chosen payment method is enabled for the order's channel. The equivalent checkout endpoint (`PATCH /api/v2/shop/orders/{tokenValue}/payments/{paymentId}`) correctly rejects out-of-channel payment methods with `HTTP 422`; the account endpoint silently accepts them and returns `HTTP 200`. An authenticated customer can therefore assign any globally enabled payment method to their own placed order, including methods that the store operator has explicitly excluded from that channel. The issue is fixed in versions: 2.0.18, 2.1.15, 2.2.6 and above. As a workaround, decorate the `Sylius\Bundle\ApiBundle\Changer\PaymentMethodChangerInterface` service in the application.

Published

Date2026-09-08

Updated

Date2026-09-08

RISK INFORMATION (Score: 4.3)

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:N

Impact Score

1.4

Exploitability

2.8

REFERENCES

https://github.com/Sylius/Sylius/security/advisories/GHSA-6955-hrm5-c4qp

CVE-2026-53637

SUMMARY

Sylius is an Open Source eCommerce Framework on Symfony. Versions 2.0.0 through 2.0.17, 2.1.0 through 2.1.14, and 2.2.0 through 2.2.5 contain an improper workflow enforcement vulnerability in the cart `FormComponent`. When an order is completed while its cart page remains open, the stale LiveComponent does not detect the order’s changed state and continues to permit cart actions, allowing an authenticated customer to modify or permanently delete an already completed order. Versions 2.0.18, 2.1.15, and 2.2.6 contain a patch. As a workaround, deployments can copy the patched `FormComponent` into the application's `src/` directory and override the `sylius_shop.twig.component.cart.form` service definition to use that class.

Published

Date2026-09-08

Updated

Date2026-09-08

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:H/A:N

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://github.com/Sylius/Sylius/security/advisories/GHSA-5597-7rmh-97q5

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

NovogeneAIT Genomics Vendor Cyber Rating & Cyber Score

NovogeneAIT Genomics A.I CyberSecurity Scoring

NovogeneAIT Genomics CyberSecurity News & History

NovogeneAIT Genomics Company Scoring based on AI Models